Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Letters

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2009.11.009PMID 20034732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype.

  2009cited by this paper
• Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.

  2009cited by this paper
• Functional Interaction between the Fanconi Anemia D2 Protein and Proliferating Cell Nuclear Antigen (PCNA) via a Conserved Putative PCNA Interaction Motif*

  2009cited by this paper
• Biomarkers and Mechanisms of FANCD2 Function

  2008cited by this paper
• FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3

  2008cited by this paper
• Downregulation of Fanconi Anemia Genes in Sporadic Head and Neck Squamous Cell Carcinoma

  2007cited by this paper
• Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins

  2007cited by this paper
• Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.

  2007cited by this paper
• Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.

  2007cited by this paper
• Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.

  2007cited by this paper
• Oxaliplatin and capecitabine (XELOX) as first-line therapy for metastatic or relapsed squamous cell carcinoma of the head and neck

  2007cited by this paper
• Fanconi anemia.

  2006cited by this paper
• Evidence for subcomplexes in the Fanconi anemia pathway.

  2006cited by this paper
• DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.

  2006cited by this paper
• Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer.

  2006cited by this paper
• The structure‐specific endonuclease Mus81–Eme1 promotes conversion of interstrand DNA crosslinks into double‐strands breaks

  2006cited by this paper
• FANCC, FANCE, and FANCD2 Form a Ternary Complex Essential to the Integrity of the Fanconi Anemia DNA Damage Response Pathway*

  2005cited by this paper
• A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair.

  2005cited by this paper
• Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export.

  2005cited by this paper
• Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.

  2005cited by this paper
• Fanconi anemia (cross)linked to DNA repair.

  2005cited by this paper
• Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype

  2005cited by this paper
• The Fanconi Anemia/BRCA pathway: new faces in the crowd.

  2005cited by this paper
• Disruption of Murine Mus81 Increases Genomic Instability and DNA Damage Sensitivity but Does Not Promote Tumorigenesis

  2005cited by this paper
• Functional Screen of the Fanconi Anemia Pathway in Cancer Cells by Fancd2 Immunoblot

  2004cited by this paper
• Functional Interaction of Monoubiquitinated FANCD2 and BRCA2/FANCD1 in Chromatin

  2004cited by this paper
• Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

  2004cited by this paper
• Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA

  2004cited by this paper
• Fanconi anaemia proteins: major roles in cell protection against oxidative damage.

  2003cited by this paper
• Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia.

  2002cited by this paper
• Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.

  2001cited by this paper
• Apoptosis, p53, and tumor cell sensitivity to anticancer agents.

  1999cited by this paper
• Immortalization of four new fanconi anemia fibroblast cell lines by an improved procedure

  1996cited by this paper
• Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents.

  1982cited by this paper

• Exploratory Gene Expression Profiling of Cisplatin-Induced Neurotoxicity in Rat Brain

  2025cites this paper
• FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds.

  2024cites this paper
• Crosstalk of different cell-death patterns predicts prognosis and drug sensitivity in glioma

  2024cites this paper
• Assessment of Oxaliplatin-Loaded Iodine Nanoparticles for Chemoradiotherapy of Human Colorectal Cancer (HT-29) Cells

  2022cites this paper
• Abnormally Expressed Ferroptosis-Associated FANCD2 in Mediating the Temozolomide Resistance and Immune Response in Glioblastoma

  2022cites this paper
• In-vitro/in-vivo evaluation of Paclitaxel Freeze-Dried micellar nanoparticles intended for buccal delivery

  2021cites this paper
• Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene.

  2020cites this paper
• Chitosan nanoparticles loading oxaliplatin as a mucoadhesive topical treatment of oral tumors: iontophoresis further enhances drug delivery ex vivo.

  2019cites this paper
• Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas

  2019cites this paper
• Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer

  2018cites this paper
• A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents

  2017cites this paper
• Nuclear alpha spectrin: Critical roles in DNA interstrand cross-link repair and genomic stability

  2016cites this paper
• Nuclear α Spectrin Differentially Affects Monoubiquitinated Versus Non‐Ubiquitinated FANCD2 Function After DNA Interstrand Cross‐Link Damage

  2016cites this paper
• An investigation of the pharmacogenetic basis of toxicity to platinum chemotherapy agents

  2016influential citation
• A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

  2016cites this paper
• p 53 mediated apoptosis in osteosarcoma MG-63 cells by inhibition of FANCD 2 gene expression

  2015cites this paper
• p53 mediated apoptosis in osteosarcoma MG-63 cells by inhibition of FANCD2 gene expression.

  2015cites this paper
• Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation.

  2015cites this paper
• Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers

  2015cites this paper
• Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy - a review.

  2014cites this paper
• Gene signatures of drug resistance predict patient survival in colorectal cancer

  2014cites this paper
• Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993)

  2014cites this paper
• DNA Damage Proteins and Response to Therapy in Head and Neck Cancer

  2014cites this paper
• Therapeutics , Targets , and Chemical Biology EGFR-Activating Mutations Correlate with a Fanconi Anemia – likeCellular Phenotype That Includes PARP Inhibitor Sensitivity

  2013cites this paper
• EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

  2013cites this paper
• Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines.

  2013cites this paper
• Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues

  2013influential citation
• Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells

  2012cites this paper
• Targeting Homologous Recombination Repair in Cancer

  2012cites this paper
• Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact

  2011cites this paper
• FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.

  2011cites this paper
• DNA Helix Destabilization by Alkylating Agents: From Covalent Bonding to DNA Repair

  2011cites this paper
• Identification of Novel Molecular Targets of Resveratrol in Colorectal Carcinogenesis

  2011cites this paper
• Stem cell characteristics of cell sub-populations in cell lines derived from head and neck cancers of Fanconi anemia patients.

  2011cites this paper
• Molecular Targets of Resveratrol in Carcinogenesis

  2011cites this paper